Company Overview of Invitae Corporation
Invitae Corporation, a genetic information company, focuses on bringing comprehensive genetic information into mainstream medical practice to enhance the quality of healthcare in the United States, Canada, Israel, and internationally. The company processes DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patients using an integrated portfolio of laboratory processes, software tools, and informatics capabilities. It provides a diagnostic service comprising hundreds of genes for various genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas. The company...
458 Brannan Street
San Francisco, CA 94107
Founded in 2010
Key Executives for Invitae Corporation
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $331.0K
Total Annual Compensation: $251.0K
Compensation as of Fiscal Year 2015.
Invitae Corporation Key Developments
Invitae Corporation Announces Availability of New Genetic Test for Diagnosis of Spinal Muscular Atrophy
Mar 22 17
Invitae Corporation announced the availability of a new genetic test for the diagnosis of Spinal Muscular Atrophy (SMA), a neuromuscular disease that is one of the lethal genetic disorders among infants as well as a significant cause of progressive neuromuscular disease in childhood. The new test, announced during the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, features a novel, custom methodology that offers significant improvements over current testing approaches. Accurate testing of both genes is critical for the diagnosis and treatment of SMA. Testing for the absence of functional SMN1 is the basis of diagnosis and can distinguish the condition from other neuromuscular diseases such as muscular dystrophy. Understanding the number of copies of the SMN2 gene can provide prognostic information and help guide therapeutic choices and clinical trial participation. However, due to the similarities between the two genes, testing is technically challenging and reliably accurate tests have not previously been widely available. Invitae's approach leverages advanced next generation sequencing and a customized bioinformatics solution to accurately identify sequence changes and copy number changes in both genes from a single test. Analysis of SMN1 and SMN2 is now available from Invitae as a stand-alone test, and it has been added to a number of the company's comprehensive neuromuscular and neuropathy panels, allowing physicians the ability to test for SMA alongside a number of other neurological disorders for no additional cost.
Invitae Corporation Presents at Cowen and Company 37th Annual Health Care Conference, Mar-06-2017 04:00 PM
Feb 21 17
Invitae Corporation Presents at Cowen and Company 37th Annual Health Care Conference, Mar-06-2017 04:00 PM. Venue: The Boston Marriott Copley Place, 110 Huntington Avenue, Boston, Massachusetts, United States.
Invitae Corporation Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016
Feb 13 17
Invitae Corporation announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported net loss of $24.8 million or $0.69 per basic and diluted share on revenue of $9.2 million compared to net loss of $24.3 million or $0.76 per basic and diluted share on revenue of $3.2 million reported in the same period last year. Loss from operations was $24.95 million against $24.3 million reported last year.
For the year, the company reported net loss of $100.3 million or $3.02 per basic and diluted share on revenue of $25.15 million compared to net loss of $89.8 million or $3.18 per basic and diluted share on revenue of $8.4 million reported in the same period last year. Loss from operations was $100.2 million against $89.5 million reported last year. Cash used in operating activities in 2016 amounted to $76.3 million, as compared to $80.7 million in 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions